Extended Data Fig. 3: Forest plot of the analysis of event-free survival in prespecified subgroups for sasanlimab + BCG-I vs BCG-I+M. | Nature Medicine

Extended Data Fig. 3: Forest plot of the analysis of event-free survival in prespecified subgroups for sasanlimab + BCG-I vs BCG-I+M.

From: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

Extended Data Fig. 3

The hazard ratio for EFS in all patients was calculated on the basis of an analysis stratified by the presence of carcinoma in situ at randomization (yes or no) and geography (US, Western Europe and Canada, or rest of world). In each subgroup, the hazard ratio for EFS was estimated with the use of unstratified Cox proportional-hazards models. Data are presented as hazard ratio (center) with 95% confidence intervals (error bars). BCG-I+M, induction and maintenance regimen of intravesical Bacillus Calmette-Guérin; CIS, carcinoma in situ; CRF, case report form; EFS, event-free survival.

Back to article page